drugset / Trial / NCT00511810

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

NCT00511810

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.

Timeline

Start
2007-08
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Omega-3 fatty acids Unknown 2.4 g
Subject Omega-3 fatty acids Unknown 15 g